Kymriah Archives -

FDA hastens development of Novartis’ Kymriah in follicular lymphoma

https://pharmaphorum.com/news/fda-hastens-development-of-novartis-kymriah-in-follicular-lymphoma/

Real-world data backs Kymriah’s safety profile, says Novartis

https://pharmaphorum.com/news/real-world-data-backs-kymriahs-safety-profile-says-novartis/

Novartis’ Kymriah okayed for funding in Scotland for lymphoma

https://pharmaphorum.com/news/novartis-kymriah-okayed-for-funding-in-scotland-for-lymphoma/

Will cell and gene therapies disrupt reimbursement?

https://deep-dive.pharmaphorum.com/magazine/disruptive-technologies/will-cell-and-gene-therapies-disrupt-drug-reimbursement/

Scotland says no to Yescarta, but backs Kymriah

https://pharmaphorum.com/news/scotland-says-no-to-yescarta-but-backs-kymriah/

NICE approves Novartis’ CAR-T therapy for diffuse large B-cell lymphoma

https://pharmaphorum.com/news/nice-approves-novartis-car-t-therapy-for-diffuse-large-b-cell-lymphoma/

Novartis offers to buy Kymriah manufacturer

https://pharmaphorum.com/news/novartis-offers-to-buy-kymriah-manufacturer/

Jimenez to step down as Novartis chief, Narasimhan takes over

https://pharmaphorum.com/news/jimenez-step-novartis-chief-narasimhan-takes/

Oxford BioMedica could get $100m following CAR-T approval

https://pharmaphorum.com/news/oxford-biomedica-get-100-following-car-t-approval/

Search